Trial Profile
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics
- Acronyms N-Dur
- 13 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 13 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 02 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.